We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of Hit Compounds Using Artificial Intelligence for the Management of Allergic Diseases.
- Authors
Byun, Junhyoung; Tai, Junhu; Kim, Byoungjae; Kim, Jaehyeong; Jung, Semyung; Lee, Juhyun; Song, Youn woo; Shin, Jaemin; Kim, Tae Hoon
- Abstract
This study aimed to identify and evaluate drug candidates targeting the kinase inhibitory region of suppressor of cytokine signaling (SOCS) 3 for the treatment of allergic rhinitis (AR). Utilizing an artificial intelligence (AI)-based new drug development platform, virtual screening was conducted to identify compounds inhibiting the SH2 domain binding of SOCS3. Luminescence assays assessed the ability of these compounds to restore JAK-2 activity diminished by SOCS3. Jurkat T and BEAS-2B cells were utilized to investigate changes in SOCS3 and STAT3 expression, along with STAT3 phosphorylation in response to the identified compounds. In an OVA-induced allergic rhinitis mouse model, we measured serum levels of total IgE and OVA-specific IgE, performed real-time PCR on nasal mucosa samples to quantify Th2 cytokines and IFN-γ expression, and conducted immunohistochemistry to analyze eosinophil levels. Screening identified 20 hit compounds with robust binding affinities. As the concentration of SOCS3 increased, a corresponding decrease in JAK2 activity was observed. Compounds 5 and 8 exhibited significant efficacy in restoring JAK2 activity without toxicity. Treatment with these compounds resulted in reduced SOCS3 expression and the reinstatement of STAT3 phosphorylation in Jurkat T and BEAS-2B cells. In the OVA-induced allergic rhinitis mouse model, compounds 5 and 8 effectively alleviated nasal symptoms and demonstrated lower levels of immune markers compared to the allergy group. This study underscores the promising nonclinical efficacy of compounds identified through the AI-based drug development platform. These findings introduce innovative strategies for the treatment of AR and highlight the potential therapeutic value of targeting SOCS3 in managing AR.
- Subjects
NASAL mucosa; ALLERGIES; SUPPRESSORS of cytokine signaling; DISEASE management; ARTIFICIAL intelligence; DRUG development; NASAL cannula
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 4, p2280
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25042280